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GATA4 and GATA5 are PotentialTumor Suppressors and
Biomarkers in Colorectal Cancer
DebbyM.E.I. Hellebrekers,1Marjolein H.F.M. Lentjes,1SandraM. van den Bosch,1Veerle Melotte,1
Kim A.D.Wouters,1Kathleen L.J. Daenen,1KimM. Smits,2 Yoshimitsu Akiyama,4 YasuhitoYuasa,4
Silvia Sanduleanu,3 Carolina A.J. Khalid-de Bakker,3 DaisyJonkers,3Matty P. Weijenberg,2
Joost Louwagie,5Wim van Criekinge,5 Beatriz Carvalho,6 Gerrit A.Meijer,6 Stephen B. Baylin,7
James G. Herman,7 Adriaan P. de BruI«ne,1andManonvan Engeland1
Abstract Purpose:The transcription factors GATA4 and GATA5 are involved in gastrointestinal develop-
ment and are inactivated by promoter hypermethylation in colorectal cancer. Here, we evaluated
GATA4/5 promoter methylation as potential biomarkers for noninvasive colorectal cancer detec-
tion, and investigated the role of GATA4/5 in colorectal cancer.
Experimental Design:PromotermethylationofGATA4/5 was analyzed in colorectal tissue and
fecal DNA from colorectal cancer patients and healthy controls using methylation-specific PCR.
Thepotential functionofGATA4/5 as tumor suppressorswas studiedby inducingGATA4/5over-
expression in human colorectal cancer cell lines.
Results: GATA4/5 methylation was observed in 70% (63/90) and 79% (61/77) of colorectal
carcinomas, respectively, and was independent of clinicopathologic features. Methylation fre-
quencies in normal colon tissues from noncancerous controls were 6% (5 of 88, GATA4; P <
0.001) and13% (13 of100,GATA5; P < 0.001). GATA4/5 overexpression suppressed colony for-
mation (P < 0.005), proliferation (P < 0.001), migration (P < 0.05), invasion (P < 0.05), and an-
chorage-independent growth (P < 0.0001) of colorectal cancer cells. Examination of GATA4
methylation in fecal DNA from two independent series of colorectal cancer patients and controls
yielded a sensitivity of 71% [95% confidence interval (95% CI), 55-88%] and specificity of 84%
(95% CI, 74^95%) for colorectal cancer detection in the training set, and a sensitivity of 51%
(95% CI, 37^65%) and specificity of 93% (95% CI, 84-100%) in the validation set.
Conclusions:MethylationofGATA4/5 is a commonand specific event in colorectal carcinomas,
and GATA4/5 exhibit tumor suppressive effects in colorectal cancer cells in vitro.GATA4 methyl-
ation in fecal DNAmay be of interest for colorectal cancer detection.
Early detection of colorectal cancer and high-risk precursor
lesions will improve cure rates (1). The gold standard for
colorectal cancer detection is colonoscopy, but due to its
invasive nature, many patients refrain from undergoing
colonoscopy. Therefore, noninvasive screening modalities to
select patients at risk of colorectal cancer for colonoscopy, are
needed. Currently, testing for the presence of fecal occult blood
is used (2, 3). Despite its low sensitivity, fecal occult blood
testing has been shown to reduce the incidence and risk of
colorectal cancer death when used programmatically (1, 2,
4, 5). A promising noninvasive colorectal cancer screening
modality is the detection of colorectal cancer–specific genetic
alterations in stool-derived DNA (6–9), but it needs improve-
ment in terms of sensitivity and cost effectiveness.
Promoter CpG island hypermethylation analysis of serum
and feces has the potential to be used as a noninvasive test for
the early diagnosis of (colorectal) cancers (10–15). However,
because promoter methylation is also associated with aging
(16) and chronic inflammation (17–19), proper selection of
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methylation markers is crucial for sensitive and specific
detection of colorectal cancer.
Transcription factors GATA4 and GATA5 play an essential
role in the development and differentiation of the gastrointes-
tinal tract and are suggested to be involved in colorectal cancer
development (20–23). However, the (tumor suppressor)
function of these genes is poorly understood.
Here we examined promoter hypermethylation ofGATA4/5 in
large, well-characterized series of colorectal cancers and non-
cancerous colorectal mucosa, and compared GATA4/5 methyl-
ation frequencies with those of other genes functionally involved
and frequently methylated in colorectal cancer. In addition, we
investigated the function of GATA4/5 in human colorectal
cancer cells by transfecting these cells with a GATA4/5 expression
vector and measuring colony formation, proliferation, migra-
tion, invasion, and anchorage-independent growth. Finally, we
evaluated the use of GATA4 methylation in fecal DNA as a
potential biomarker for early colorectal cancer detection.
Materials andMethods
Study population. Formalin-fixed, paraffin-embedded colorectal
mucosa tissue of colorectal cancer patients (n = 102) and patients
without cancer (n = 230) over 50 y of age were retrospectively collected
from the archive of the Department of Pathology of the Maastricht
University Medical Center (Supplementary Fig. S1, Supplementary
Table S1, and Supplementary Methods). An additional, independent set
of 716 paraffin-embedded colorectal cancers was derived from patients
participating in the prospective Netherlands Cohort Study on Diet and
Cancer (NLCS; refs. 24, 25). Tissue samples were handled and analyzed
in a blinded fashion during collection, storage, DNA isolation, and PCR
analysis. This study was approved by the Medical Ethical Committee of
the Maastricht University Medical Center.
Methylation-specific PCR, BRAF mutation and microsatellite instability
analysis. A 5-Am section of each tissue block was stained with H&E
and revised by a pathologist (AdB). Five 20-Am sections were
deparaffinated prior to DNA-isolation using the Puregene DNA
Isolation Kit (Gentra Systems; Qiagen). Promoter CpG island methyl-
ation of GATA4, GATA5, APC, p14ARF , O6-MGMT, HLTF, p16INK4A , and
RASSF1A was determined by sodium bisulfite treatment of genomic DNA
followed by methylation-specific PCR (MSP) as described elsewhere
(25, 26). For primer sequences and MSP conditions, see Supplementary
Table S2. For analysis of BRAF mutation and microsatellite instability, see
Supplementary Methods.
Cell culture and transfections. Human HCT116 and RKO colorectal
cancer cell lines were cultured in DMEM (Invitrogen) containing 10%
fetal bovine serum (HyClone).
Full-length GATA4/5 cDNAs subcloned into the pcDNA3 vector were
named pcDNA3-GATA4 and pcDNA3-GATA5. RKO cells were trans-
fected using Lipofectamine 2000 Reagent (Invitrogen) according to the
manufacturer’s protocol. After selection for 2 to 3 wk with 1 mg/mL
geneticin (G418; Invitrogen), individual clones were isolated. RKO
clones constitutively expressing GATA4/5 protein, named pc-GATA4-1
and pc-GATA5-1, were maintained inmedium containing G418 (1mg/mL)
and used for further experiments. Three RKO clones constitutively
expressing empty vector (pc-con-1, pc-con-2, and pc-con-3) were used,
and results of these three clonal lines were averaged and named pc-
con(1-3). HCT116 cells were transfected with the Nucleofector Kit V
(Amaxa Biosystems) using themanufacturer’s guidelines. Although up to
30 single colonies were picked after 2 to 3 wk selection with 400 Ag/mL
G418, HCT116 clonal lines constitutively expressing GATA4/5 protein
could not be maintained. Therefore, HCT116 cells were transfected with
control construct (empty vector; pcDNA3), pcDNA3-GATA4 or pcDNA3-
GATA5, selected for 10 d with G418 (400 Ag/mL), and these
heterogeneous cell populations, named pc-con, pc-GATA4, and pc-
GATA5, respectively, were used for further experiments using medium
without G418. For real-time reverse transcription-PCR, Western Blot,
colony formation, cell proliferation,migration, invasion, and anchorage-
independent growth assays, see Supplementary Methods.
Collection of fecal DNA. Colonoscopy negative control stool
samples (n = 75) were obtained from a population of healthy subjects
over 50 y of age who were screened within the framework of a
workplace-based community colorectal cancer screening study at the
Maastricht University Medical Center. The Medical Ethics Committee of
the Maastricht University Medical Center and the Dutch Health Council
approved the study. Stool samples from colonoscopy-confirmed
colorectal cancer patients (n = 75) were collected at the VU University
Medical Center in Amsterdam. For the subjects’ characteristics, see
Supplementary Table S3. Written informed consent was obtained for all
stool samples. Control stool samples and a subset of colorectal cancer
samples were collected within 2 wk prior to colonoscopy. Some colorectal
cancer stool samples were collected 5 to 7 d following colonoscopy.
Colorectal cancer stool samples were only collected when the tumor was
not resected after colonoscopy. Stool samples were stored and processed
(see Supplementary Methods section) in one center, and handled and
analyzed in a blinded fashion during collection, storage, DNA isolation,
and PCR analysis.
Quantitative MSP. Quantitative MSP (qMSP) was applied on a
7900HT fast real-time PCR system (Applied Biosystems). The PCR
reaction was carried out in 12 AL volume containing buffer [16.6
mmol/L (NH4)2SO4, 67 mmol/L Tris, 6.7 mmol/L MgCl2, 10 mmol/L
h-mercaptoethanol], 5 mmol/L dNTP, 6 ng/AL forward primer, 18 ng/
AL reverse primer, 0.16 Amol/L molecular beacon, 0.1 Ag bovine serum
albumin, 0.4 units Jumpstart DNA Taq polymerase (Sigma Aldrich),
and 2.4 AL DNA. Cycling parameters were 5 min 95jC, followed by 45
cycles of 30 sec 95jC, 30 sec 57jC and 30 sec 72jC, followed by 5 min
72jC. A standard curve (2  106 - 20 copies) was included to determine
copy numbers of unknown samples by interpolation of their Ct values
to the standard curve. For primer and molecular beacon sequences, see
Supplementary Table S2. Receiver operator characteristic (ROC) curve
analysis was used to assess the best cutoff value (an optimal cutoff value
was determined by the point on the ROC curve closest to 100%
specificity and corresponding to the highest sensitivity), and to
determine diagnostic performance, using the area under the curve.
Positivity for GATA4 methylation was considered if a methylation value
was higher than the cutoff.
Translational Relevance
Detection of aberrantly methylated tumor suppressor
genes in stool DNA of colorectal cancer patients provides
an attractive strategy for noninvasive and early detectionof
colorectal cancer.The current article shows that GATA4/5
promoter methylation is an early, frequent, and specific
event in colorectal cancer, independentof clinicopathologic
features.We also show that GATA4 methylation is a sensi-
tive and specific biomarker for colorectal cancer detection
in stool DNA. In addition, we partly unraveled the function
of GATA4 andGATA5 in colorectal cancer, by showing that
these proteins suppress colony formation, proliferation,mi-
gration, invasion, and anchorage-independent growth of
colorectal cancer cells, indicating a tumor suppressor role
of GATA4 and GATA5 in colorectal cancer. To our knowl-
edge, this is the first study that (a) reportsonthe tumorsup-
pressive effects of GATA4 and GATA5 in colorectal cancer,
and (b) shows that GATA4 methylation is a promising bio-
marker for early colorectal cancer screening in stool DNA.
GATA4 and GATA5 as Colorectal Cancer Biomarkers
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Statistical analysis. We used Pearson’s m2 or Fisher’s exact test and
the one-way ANOVA, Kruskal-Wallis, or Mann-Whitney test where
appropriate to compare categorical and continuous patient data,
respectively. Paired samples within the group of cases were analyzed
using the Mc Nemar test and the paired t-test to compare categorical
and continuous data, respectively. Because significant differences in age
and location of the tissue were observed between colorectal cancer
patients and controls (Supplementary Table S1), logistic regression
analyses were used to adjust for age and location. Where appropriate,
the Bonferroni method was used to correct for multiple comparisons.
To examine sensitivity and specificity of every possible marker
combination, WEKA System’s Bayes Network machine learning was
applied (27). In vitro cell line experiments are given as mean values F
SE. Analysis of cell growth curves was done by means of the two-way
ANOVA test. Student’s t-test was used for analyses of 3H-thymidine
incorporation and anchorage-independent growth. Colony formation
assay, quantitative real-time reverse transcription-PCR, migration, and
invasion assays analyses were done using the Mann-Whitney rank sum
test. All P values are two-sided and P V 0.05 was considered statistically
significant. Statistical analysis was done in SPSS12.0.1.
Results
High frequencies of GATA4 and GATA5 methylation in
colorectal carcinomas and adenomas. GATA4 methylation was
detected in 70% (63/90) of colorectal carcinomas, whereas
methylation of this gene was observed in only 5 of 88 (6%) of
normal colorectal tissues from noncancerous controls were
methylated (Table 1, P < 210-11). Methylation frequencies of
GATA5 were 79% (61/77) in colorectal carcinoma tissues and
13% (13/100) in noncancerous controls (Table 1, P < 310-14).
GATA4/5 were 86% concomitantly methylated and 83%
concomitantly unmethylated in colorectal carcinomas (P <
0.0110-17; data not shown). Because promoter methylation
has been described in inflammatory conditions of the gastro-
intestinal tract (17–19), inflamed colorectal mucosa of non-
cancerous patients was added to the control group (Table 1).
This did not significantly increase GATA4/5 methylation (7%
and 12%, respectively; Table 1).
Comparing the frequencies of GATA4/5 methylation with
those of other genes reported to be frequently methylated in
colorectal cancer (APC , p14ARF ,O6-MGMT ,HLTF , p16INK4A , and
and RASSF1A; refs. 28–30; Table 1) showed that GATA4/5 do
best in terms of specificity and sensitivity, respectively (Table 1).
Furthermore, Bayesian network analysis showed that the
sensitivity of GATA4/5 methylation alone did not improve by
adding any of the other markers. In addition, no other
combination of methylation markers has a higher sensitivity
as compared with GATA4/5 alone (data not shown). No
correlation was observed between GATA4/5 methylation and
the V600E BRAF mutation (found in 13% of all carcinomas;
13/98) or microsatellite instability status (found in 15% of all
carcinomas; 15/101; data not shown).
A second independent series of colorectal cancers (NLCS;
refs. 24, 25) confirms the high frequency of GATA4 (65%; 369/
572) and GATA5 (74%; 440/592) methylation (data not
shown). Furthermore, GATA4/5 promoter methylation was
not significantly associated with tumor-node-metastasis (TNM)
stage, tumor location, sex, age at diagnosis, histologic type,
or grade of differentiation in both series (Table 2 and data
not shown).
GATA4/5 methylation frequencies of adenomas that devel-
oped synchronously or metachronously to the tumor (n = 75)
and adenomas obtained from noncancerous patients (n = 72;
10-year follow-up) did not show significant differences
between these two groups (Supplementary Table S4). No
association of GATA4/5 methylation with grade of dysplasia
was observed, but more GATA4 methylation in tubulovillous as
compared with tubular adenomas was observed (P < 0.0001,
data not shown). Frequencies of GATA4/5 methylation were
not significantly different between normal colon mucosa
obtained from colorectal cancer patients and noncancerous
controls (Supplementary Table S4). No association was found
between GATA4/5 promoter methylation in normal noncan-
cerous tissue and age at biopsy, sex, or location of the normal
tissue (data not shown).
Adenoma samples from colorectal cancer patients exhibited
significantly higher GATA4/5 methylation frequencies than
normal colon mucosa from these patients (P < 0.002 and
P < 0.0005, respectively; Supplementary Table S5). Significantly
higher GATA4/5 methylation frequencies were observed in
colorectal cancers when compared with normal colon from
colorectal cancer patients (P < 410-7 and P < 210-7,
Table 1. Methylation frequencies in colorectal carcinomas compared with noncancerous colorectal mucosa
(normal or inflamed tissue)
CRC+ CRC- P*(<) CRC- P* (<)
Carcinoma Normal Normal plus inflamed
GATA4 63/90 (70%) 5/88 (6%) 210-11 8/119 (7%) 410-14
GATA5 61/77 (79%) 13/100 (13%) 310-14 16/129 (12%) 310-16
APC 47/100 (47%) 24/103 (23%) 210-3 32/132 (24%) 910-4
p14ARF 37/86 (43%) 15/105 (14%) 210-4 19/134 (14%) 410-5
O6-MGMT 50/96 (52%) 21/105 (20%) 210-5 30/139 (22%) 910-6
HLTF 50/96 (52%) 19/103 (18%) 710-5 21/134 (16%) 210-6
p16INK4A 59/95 (62%) 14/68 (21%) 310-7 25/97 (26%) 510-7
RASSF1A 25/100 (25%) 14/101 (14%) ns 16/131 (12%) 210-2
NOTE: Methylation frequencies are represented as the number of methylated samples/(divided by) the total number of samples analyzed
(percentage). Logistic regression was used to adjust for age and location.
Abbreviations: CRC+, colorectal cancer patients; CRC-, noncancerous individuals; ns, not significant.
*Bonferroni-corrected P value.
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respectively). Although more methylation of GATA4/5 was
observed in carcinomas than in adenomas from colorectal
cancer patients, this was not statistically significant (Supple-
mentary Table S5).
Reduced colony formation and proliferation of colorectal cancer
cells by GATA4 and GATA5. The high frequency of GATA4/5
promoter methylation, as well as the frequent loss of the
GATA4 locus (8p23.1-p22), suggests that silencing these genes
might confer a selection advantage. Therefore, expression
constructs harboring full-length GATA4/5 cDNA were intro-
duced into RKO in which GATA4 is present but GATA5 is
silenced (22), showing reduced numbers of G418-resistant
colonies (86% and 76% reduction, respectively) compared with
transfection of empty vector (Fig. 1A; P < 0.005). Comparable
results were found when using HCT116, in which both GATA4/
5 are absent (ref. 22; Fig. 1B).
Single colonies of RKO and HCT116 transfectants were
picked and expanded. For RKO, one clone with constitutively
higher levels of GATA4 mRNA and protein than control
transfectants was obtained (pc-GATA4-1), and one clone stably
expressing GATA5 (pc-GATA5-1; Fig. 2A). Cell growth of three
RKO control clones constitutively expressing empty vector (pc-
con-1, -2, -3) was comparable and averaged [pc-con(1-3)], and
proliferation of the GATA4/5 clones was significantly reduced
compared with control clones (Fig. 2B and C). In contrast to
RKO, HCT116 single-cell clones stably expressing GATA4/5
protein could not be maintained. Therefore, these cells were
transiently transfected and selected with G418 for 10 days, and
then seeded for functional assays. GATA4 and GATA5 trans-
fectants expressed mRNA and protein of GATA4 and GATA5,
respectively, and showed significantly decreased proliferation
(32% and 45% inhibition after 5 days, respectively) as
compared with control transfectants (pc-con; Supplementary
Fig. S2). The percentage of cells with sub-diploid DNA content
was measured using flow cytometry, but no differences in
apoptosis or total cell death were observed (data not shown).
GATA4andGATA5suppressmigration, invasion,andanchorage-
independent growth of colorectal cancer cells. We next examined
Fig. 1. GATA4 and GATA5 inhibit colony
formation of human colorectal cancer cells.
A and B, colony formation of RKO (A) and
HCT116 (B) cells transfected with a control
vector (pc-con) or a GATA4 (pc-GATA4)
or GATA5 (pc-GATA5) expression vector
and selected for 2 wk with G418.
Quantification of colony formation is
presented as mean values (F SE) relative
to control transfectants (pc-con) of three
independent experiments (*P < 0.005).
Table 2. GATA4/5 methylation frequencies in




I 11/15 (73%) 13/15 (87%)
II 21/32 (66%) 21/29 (74%)
III 25/34 (74%) 19/25 (76%)
IV 6/9 (67%) 8/8 (100%)
Tumor Location
Proximal 32/41 (78%) 31/36 (86%)
Distal 31/47 (66%) 29/39 (74%)
Sex
Male 29/42 (69%) 29/37 (78%)
Female 34/48 (71%) 32/40 (80%)
Age at diagnosis*
V mean 28/38 (74%) 26/34 (76%)
> mean 35/52 (67%) 35/43 (81%)
Histologic type
Adenocarcinoma 50/75 (67%) 49/65 (75%)
Mucinous carcinoma 13/15 (87%) 12/12 (100%)
Differentiation
Poor 6/8 (75%) 6/7 (86%)
Moderate 52/71 (73%) 47/59 (80%)
Well 5/11 (46%) 8/11 (73%)
NOTE: No significant correlations were found.
*Individuals are divided into two groups: those with an age
smaller than or equal to the mean age of the study population and
those with an age higher than the mean age.
GATA4 and GATA5 as Colorectal Cancer Biomarkers
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the effects of GATA4/5 on migration and invasion of
colorectal cancer cells using the modified Boyden chamber
assay. Migration of GATA4/5 RKO clones was significantly
lower when compared with control clones (Fig. 3A; P < 0.05).
This was confirmed in HCT116, showing significantly
decreased migration of the GATA4/5-transfected cells (68%
and 73% inhibition, respectively) when compared with
control transfectants (Fig. 3B). Invasion of GATA4 and GATA5
RKO clones through matrigel-layered transwell membranes
was also lower than that of control clones (Fig. 3C; P < 0.05).
Similarly, the invasive activity of GATA4/5 HCT116 trans-
fectants was also significantly reduced (87% and 74%
inhibition, respectively) compared with empty vector trans-
fected cells (Fig. 3D and Supplementary Fig. S3). Anchorage-
independent growth of RKO monoclonal cell lines was assessed
by soft agar colony formation. The number of colonies formed by
GATA4/5 RKO clones was significantly lower (59% and 66%
inhibition, respectively) compared with control clones (Supple-
mentary Fig. S4; P < 0.0001). Furthermore, GATA4/5 colonies
were smaller than those produced by control transfectants
(Supplementary Fig. S4).
GATA4 methylation in fecal DNA as a potential biomarker for
colorectal cancer detection. Because GATA4 methylation was
most specific (Table 1) and addition of GATA5 did not
significantly increase sensitivity compared with GATA4 alone
(data not shown), we further analyzed GATA4 methylation in
fecal DNA as a potential biomarker. Stool samples were
collected from colorectal cancer patients (n = 28), covering all
stages of colorectal cancer, and 45 colonoscopy negative
controls. GATA4 methylation of fecal DNA was determined
by qMSP. The area under the curve in the ROC curve was 81%
[95% confidence interval (95% CI), 70-89%]; Fig. 4. The
optimal GATA4 methylation cutoff value was 8.1 (Fig. 4). Using
this cutoff, GATA4 methylation was detected in fecal DNA from
20 of 28 patients and in 7 of the 45 control individuals,
yielding a sensitivity of 71% (95% CI, 55-88%) and a specificity
of 84% (95% CI, 74-95%). Because the mean age of the cases
and controls differed significantly, ROC-GLM regression
analysis was used to assess the accuracy of GATA4 promoter
methylation after adjustment for age (31). Age did not
significantly influence the accuracy (P = 0.71, ROC-Generalized
Linear Model regression model).
Sensitivity and specificity (using a GATA4 cutoff value 8.1)
was validated in an independent set of stool samples from
colorectal cancer patients (n = 47) and controls (n = 30). This
resulted in a sensitivity of 51% (95% CI, 37-65%) and a
specificity of 93% (95% CI, 84-100%) of GATA4 methylation
in fecal DNA.
Sensitivity of GATA4 promoter methylation in fecal DNA
for detecting early-stage (TNM stage I and II) and advanced-
stage (TNM stage III and IV) colorectal cancer was 10 of 18
(55%; early stage) versus 10 of 10 (100%; advanced stage) for
the training set, and 14 of 29 (48%; early stage) versus 10 of
17 (59%; advanced stage) in the validation set. Although this
pilot study shows proof of principle for detecting GATA4
promoter methylation in stool, it seems that early-stage
colorectal cancers shed less DNA when compared with
advanced-stage colorectal cancers, which emphasizes the need
for sensitive assays to isolate/capture DNA from early-stage
colorectal cancers.
For a subset (n = 19) of cases of which fecal DNA was
examined for GATA4 promoter CpG island methylation, the
Fig. 2. GATA4 and GATA5 inhibit proliferation of human colorectal cancer cells. A, bar graphs, GATA4 and -5 mRNA expression measured by real-time reverse
transcription-PCR in RKOmonoclonal cell lines.The pc-GATA4-1and pc-GATA5-1clones constitutively express GATA4 and -5, respectively, and pc-con(1-3) represents
the average of three control (empty pcDNA3 vector) clones. Results are plotted as mean values (F SE) of relative mRNA expression compared with pc-con(1-3) (GATA4)
or as mean values (F SE) of expression (calculated as 2-dCt; GATA5) of three independent experiments [*P < 0.05 versus pc-con(1-3)]. N/E, not expressed. Gel images,
Western blot analysis of GATA4 and GATA5 protein in nuclear extracts of RKO cells. Only1of 3 control clones are shown. B, cell growth of RKOmonoclonal cell lines.
Results are plotted as mean values (F SE) of cell numbers of three independent experiments [*P < 0.01versus pc-con(1-3), **P < 0.001versus pc-con(1-3)]. C, proliferation
measured by 3H-thymidine incorporation. Data are expressed as mean relative proliferation values (F SE) compared with pc-con(1-3) of three independent triplicate
experiments [*P < 0.0001versus pc-con(1-3)].
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matching formalin-fixed paraffin-embedded primary tumor
tissue was available. GATA4 promoter methylation was
detected in 16 of 19 primary colorectal cancers, and 10 of
these 16 colorectal cancers also exhibited methylation in the
matched stool samples, yielding an analytical sensitivity of 63%
(95% CI, 39-86%; data not shown).
Discussion
Loss of GATA4/5 expression due to promoter hypermethy-
lation has been reported in primary colorectal, gastric,
esophageal, lung, ovarian, and pancreatic (GATA5 only) cancer
(22, 32–35). To analyze the potential of GATA4/5 as
methylation markers for detection of colorectal cancer, we
analyzed large series of colorectal cancer patients and controls
and showed that methylation of GATA4 (70%) and GATA5
(79%) occurs at high frequencies in colorectal cancers and at
low levels in normal colorectal mucosa (6 and 13%,
respectively). Methylation frequencies of GATA4/5 are not
increased in inflammatory colorectal tissues. GATA4/5 methyl-
ation is highly prevalent in colorectal adenomas, suggesting
that methylation of GATA4/5 is an early event in colorectal
carcinogenesis. Lack of association of GATA4/5 methylation
with clinicopathologic characteristics indicates that GATA4/5
methylation may be equivalently sensitive to early- and late-
stage colorectal cancer, and to proximal as well as distal colo-
rectal cancer, thereby covering all colorectal cancer phenotypes,
including microsatellite instable and chromosomal instable
tumors. These findings indicate that methylation of GATA4/5
may be suitable markers for early diagnosis of colorectal cancer.
Methylation analysis of six other genes frequently and
functionally methylated in colorectal cancer (28–30) showed
frequent methylation of APC , p16INK4A , and O6-MGMT in
normal and inflamed colorectal mucosa. Whether methylation
of APC and p16INK4A in normal colorectal mucosa represents a
field effect (and thus a prognostic marker) as was published for
O6-MGMT (36) is not clear from this study.
Well-defined molecular markers will be helpful for noninva-
sive early diagnosis of colorectal cancer and might reduce
mortality from this disease. The combined sensitivity and
specificity of GATA4 methylation for colorectal cancer detection
compares well with other fecal DNA methylation markers such
as SFRP2 , vimentin, and HIC1 (10, 11, 15). Nevertheless,
increasing the sensitivity of GATA4 methylation in fecal DNA is
required to increase the applicability of this screening test. A
higher sensitivity for the stool GATA4 MSP test could be
Fig. 3. GATA4 and GATA5 decrease migration and invasion
of human colorectal cancer cells. A and B, migration of
RKO cell clones (A) and HCT116 cells (B) through
transwells without matrigel, measured by direct counting of
trespassed cells. Data are presented as mean relative
numbers (FSE) ofmigrated cells from several fields (200)
of two independent experiments [*P < 0.05 versus
pc-con(1-3) (A) or versus pc-con (B)]. C and D, invasion
of RKO cell clones (C) and HCT116 cells (D) through
transwells with matrigel. Results represent mean relative
counts (FSE) of trespassed cells from several fields (200)
of two independent experiments [*P < 0.05 versus
pc-con(1-3) (C) or versus pc-con (D)].
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achieved using optimal isolation protocols for fecal DNA. For
example, using methyl binding domain protein columns to
capture methylated DNA, which have been shown to markedly
increase sensitivity without decreasing specificity (37), could be
interesting in this respect. Also, identification of complemen-
tary (epi)genetic markers is required in order to obtain a
multigene assay to augment the diagnostic accuracy of fecal
DNA testing. Machine learning has revealed that neither
addition of any of the other genes we tested nor a different
gene panel outdoes the sensitivity of GATA4 and GATA5
methylation in primary colorectal carcinomas. This indicates
that none of the other genes were complementary to the
GATA4/5 markers in primary colorectal carcinomas, and
suggests the existence of a subset of colorectal cancers with
extensive promoter methylation and a subset without methyl-
ation of the markers tested in this study. When comparing
GATA4 methylation in stool DNA with the corresponding
tumor tissue, two cases were identified in which GATA4
methylation was found in stool DNA in the absence of
methylation in the associated colorectal cancer tissue. This
discrepancy might be due to the stool sample containing tumor
cells from an area separate from where the tissue DNA was
extracted, reflecting heterogeneity of GATA4 promoter methyl-
ation in the tumor, or might be derived from additional tumors
located upstream in the gastrointestinal tract such as esopha-
geal or gastric tumors. In addition, the analytical sensitivity of
63% reveals that some of the patients with GATA4 methylation
in the primary colorectal cancer lacked methylation in the
stool, which might result from the situation that detectable
amounts of tumor cells may not have shed into the feces when
it was collected.
For methylation analysis of stool DNA, qMSP was the
method of choice, because this approach allows robust and
sensitive automated analysis of clinical samples for use in
molecular screening approaches, and the specificity of this
approach is enhanced by using labeled internal probes.
GATA4/5 have been implicated in cancer development, in
which they would behave as tumor suppressors by activating
the promoters of antitumor genes (22, 38). However, to our
knowledge, the tumor suppressive effects of these genes have
never been reported in colorectal cancer, but only in GATA4-
transfected ovarian tumor cells (38). Here, we show that
introduction of GATA4/5 into human colorectal cancer cell
lines by transient and stable transfection results in inhibition of
colony formation, cell growth, migration, invasion, and
anchorage-independent growth in vitro, suggesting that these
genes are relevant tumor suppressor genes in colorectal cancer.
However, the downstream target genes of GATA4/5 inducing
the above mentioned effects remain to be identified.
In conclusion, we found that GATA4/5 exhibit tumor
suppressive activities in colorectal cancer cells in vitro and
show that promoter hypermethylation of GATA4/5 is frequent
and specific in primary colorectal cancers. GATA4 methylation
in fecal DNA has potential to be used in a biomarker panel for
improving preselection tests for colonoscopy.
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